The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Findings of a Study With a Novel Antibody-Drug Conjugate in Ovarian Cancer

Jasgit Sachdev, MD
Published Online: 4:07 PM, Mon October 24, 2016

Jasgit Sachdev, MD, clinical associate professor at Translational Genomics Research Institute, discusses a recent study of novel antibody-drug conjugate targeting protein tyrosine kinase 7 (PTK7) in ovarian cancer.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.